Subcutaneous Contouring Using High Intensity Focused Ultrasound

Body Sculpting Clinical Trial

Official title:

An Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device in Subjects With Fitzpatrick IV-VI Skin Types

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01104272
• Other study ID #: LP-1100-05
• Status: Completed
• Phase: N/A
• First received: April 9, 2010
• Last updated: January 17, 2011
• Start date: April 2010
• Est. completion date: January 2011

Study information

• Verified date: January 2011
• Source: Medicis Technologies Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The device delivers High Intensity Focused Ultrasound (HIFU) energy that can disrupt subcutaneous adipose tissue (SAT) to provide a non-invasive approach to body sculpting, such as a reduction in waist circumference.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

All of the following inclusion criteria must be met at the time of screening before the subject is enrolled into the study:

1. Male or female subjects, 18 to 65 years of age

2. Body Mass Index =30

3. Thickness of subcutaneous adipose tissue in the anticipated treatment area of = 2.5 cm

4. Subjects must agree to not alter their normal and regular diet or exercise routines during the course of the study.

5. Subjects must be of African descent AND have Fitzpatrick skin types IV, V, or VI.

Exclusion Criteria:

A subject is ineligible to participate in this study if they meet any of the following exclusion criteria at screening:

1. Female subject who is pregnant (i.e., has a positive urine pregnancy test), is suspected to be pregnant, or is lactating or becomes pregnant during the course of the study. (NOTE: Females of childbearing potential must have a negative urine pregnancy test prior to enrollment in the study.)

2. Subjects diagnosed with coagulation disorders or are receiving anticoagulant therapy or medications or dietary supplements which impede coagulation or platelet aggregation.

3. Subject has diabetes or cardiovascular disease.

4. Subject has had any aesthetic procedure to the region to be treated.

5. Subject has systemic skin disease or skin disease in the areas to be treated.

6. Subject has any abnormality of the skin or soft tissues of the abdominal wall in the areas to be treated.

7. Subject has had previous open or laparoscopic surgery in the anticipated treatment area.

8. Subjects is on prescription or over the counter weight reduction medication or programs, or had weight reduction procedures (e.g.: gastric bypass, Lap-Band, etc.)

9. Subject has skin or superficial tissue that does not lie flat on its own when the subject is in the supine position.

10. Subjects undergoing chronic steroid or immunosuppressive therapy.

11. Subjects who have cardiac pacemakers or any implantable electrical device, e.g. pacemaker, defibrillator, or neurostimulators.

12. Subjects who have metal implants of any type in the area to be treated.

13. History of cancer.

14. Subjects who have sensory loss or dysesthesia in the area to be treated.

15. Subject currently uses illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day).

16. Subjects who cannot adhere to the study visit schedule (e.g., subjects not likely to stay in the study for a maximum of 27 weeks - screening through exit visit).

17. Subjects who are unable, or lack the capacity, to self consent.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Body Sculpting

Intervention

Device:
• LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)
Study of Adipose Tissue Treatment Using Focused Ultrasound

Locations

Country	Name	City	State
Canada	Institute of Cosmetic and Laser Surgery	Oakville	Ontario
Canada	Dr. Nowell Solish Private Office	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Medicis Technologies Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in waist circumference		12 weeks	No
Secondary	The change from Baseline in waist circumference measured after treatment, for the average of the two waist circumference measurements at the iliac crest as well as for each of the individual measurements.		4 weeks	No
Secondary	The change from Baseline in waist circumference measured after treatment, for the average of the two waist circumference measurements at the iliac crest as well as for each of the individual measurements.		8 weeks	No
Secondary	Patient satisfaction as recorded on the Subject Satisfaction Survey after treatment.		1 week	No
Secondary	Patient satisfaction as recorded on the Subject Satisfaction Survey after treatment.		4 weeks	No
Secondary	Patient satisfaction as recorded on the Subject Satisfaction Survey after treatment.		8 weeks	No
Secondary	Patient satisfaction as recorded on the Subject Satisfaction Survey after treatment.		12 weeks	No
Secondary	Visual Analog Scale (VAS) diary to record post treatment discomfort.		1 week	No
Secondary	Improvement as determined by a Global Aesthetic Improvement Scale (GAIS) score of 'improved' or 'much improved' at each post-baseline visit, as assessed by the Investigator.		1 week	No
Secondary	Improvement as determined by a Global Aesthetic Improvement Scale (GAIS) score of 'improved' or 'much improved' at each post-baseline visit, as assessed by the Investigator.		4 weeks	No
Secondary	Improvement as determined by a Global Aesthetic Improvement Scale (GAIS) score of 'improved' or 'much improved' at each post-baseline visit, as assessed by the Investigator.		8 weeks	No
Secondary	Improvement as determined by a Global Aesthetic Improvement Scale (GAIS) score of 'improved' or 'much improved' at each post-baseline visit, as assessed by the Investigator.		12 weeks	No